OKYO Pharma at the BTIG Ophthalmology Conference
OKYO Pharma Limited, known by its ticker OKYO, is making significant strides as a clinical-stage biopharmaceutical company focused on innovative treatments for neuropathic corneal pain (NCP) and dry eye disease (DED). The company has announced its participation in the 4th Annual BTIG Ophthalmology Day, an event set to showcase the latest advancements in ophthalmic medical technologies.
Insights into NCP and DED
The field of ophthalmology presents a myriad of challenges, particularly for patients suffering from conditions such as NCP and DED. NCP often leads to extreme discomfort and is characterized by pain and sensitivity in the ocular area, which can deeply affect a person's quality of life. In contrast, dry eye disease represents a multi-billion-dollar market that requires effective therapeutic solutions. OKYO Pharma is committed to addressing these pressing health issues.
Event Participation Details
Dr. Gary S. Jacob, the CEO of OKYO Pharma, will be representing the company at the BTIG Ophthalmology Conference. His participation will include one-on-one meetings as well as a fireside chat scheduled from 2:40 to 3:15 PM. This event will allow for engaging discussions about current trends and future directions in ophthalmic therapies. The participation of over 20 medical technology and biotech companies highlights the significance of this event.
Recent Developments at OKYO
In addition to attending the BTIG conference, OKYO has been actively advancing its clinical programs. The development of OK-101, a lipid-conjugated chemokine peptide, showcases the company's innovative approach. This therapy is designed to provide lasting relief for those suffering from DED and NCP by leveraging its long-acting properties to enhance efficacy in treatment.
Understanding OK-101
OK-101 represents a breakthrough in the management of ocular conditions. Acting as an agonist for the ChemR23 receptor found on immune cells, it has demonstrated promising anti-inflammatory effects in animal studies. Recent trials have indicated that it significantly reduces pain associated with NCP and improves symptoms of dry eye disease, driving hope for patients seeking effective medication.
The Clinical Significance
The current landscape for treating NCP is sparse, with no FDA-approved therapies available. Thus, OKYO's focus on developing a solution signifies a potential game-changer in the treatment of neuropathic pain in the cornea. The results of ongoing trials are being closely monitored by both healthcare professionals and investors eager to witness outcomes that could reshape treatment protocols.
About OKYO Pharma Limited
OKYO Pharma Limited continues to pave its path in the biopharmaceutical landscape by developing novel therapies primarily for NCP and DED. With its shares traded on the NASDAQ, the company is positioned to attract attention from investors and stakeholders interested in ophthalmic advancements. For those looking to learn more about the company's vision and ongoing trials, further details can be found on their official website.
Contacting OKYO Pharma
For inquiries or additional information regarding OKYO Pharma and its initiatives, interested parties can reach out to:
- Gary S. Jacob, Chief Executive Officer - 917-497-7560
- Business Development & Investor Relations - Paul Spencer: +44 (0)20 7495 2379
Frequently Asked Questions
What is OKYO Pharma known for?
OKYO Pharma is recognized for developing innovative therapies targeting neuropathic corneal pain and inflammatory dry eye disease.
What events is OKYO Pharma participating in?
OKYO Pharma will participate in the 4th Annual BTIG Ophthalmology Conference, engaging in discussions and presentations regarding advancements in ophthalmic treatments.
What is the significance of the BTIG Ophthalmology Conference?
This conference gathers leading medical technology and biotech firms to explore emerging trends and developments in ophthalmic therapies.
How does OK-101 work?
OK-101 functions as an agonist targeting the ChemR23 G-protein coupled receptor to provide anti-inflammatory responses and pain relief in eye-related conditions.
Where can I find more information about OKYO Pharma?
More details about OKYO Pharma, including its projects and developments, can be found on their official website.
